Latest news with #CWE
Yahoo
2 days ago
- Business
- Yahoo
Neural's Partner CWE to Open Store No. 16 in the City of Bonn and Invitation to Meet Hanf.com at Mary Jane Berlin 2025
Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as one of the Germany's leading CBD retailers, are pleased to provide an update on expansion efforts in Germany. A subsidiary of CWE has signed a franchise agreement to open the first in the City of Bonn-the former capital of The Federal Republic of Germany and home to over 320,000 residents. This marks fifth franchise agreement and the second store in the state of North Rhine-Westphalia. is also proud to announce its participation in Mary Jane Berlin 2025, Europe's premier cannabis trade show and festival, taking place June 19-22, 2025 at Messe Berlin. As part of the event's vibrant exhibition floor, will showcase its latest product innovations, including premium CBD oils, sustainable hemp-based wellness items, and exclusive new lifestyle offerings. Visitors can find at Booth #G19/G20, where they will be invited to explore, sample, and connect with the team behind one of the most trusted names in the hemp space. Alex Cerveny, COO of commented: "We are excited to bring the experience to Bonn-a city with deep roots and a progressive spirit. This new franchise marks an important step in our mission to make high-quality CBD products accessible to customers across Germany. We look forward to serving the Bonn community with the same passion, integrity, and innovation that defines the brand." "We are also thrilled to be part of Mary Jane Berlin again this year and invite our friends, partners, and associates to come meet our team." Mr. Cerveny added: "This event is not just a trade show-it's a celebration of cannabis culture, innovation, and progress. We look forward to engaging with industry partners and consumers to showcase our carefully curated portfolio of CBD products, as we continue paving the way for opening more franchise locations." Now in its ninth year, Mary Jane Berlin is expected to welcome over 60,000 visitors and more than 500 exhibitors from around the world. Programming includes expert panels, live music, food trucks, and a dedicated B2B business day. About Neural Therapeutics Neural Therapeutics is a leader in ethnobotanical drug discovery, focusing on the development of therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. The Company's innovative approach to drug development involves the strategic use of sub-hallucinogenic doses of mescaline extract, enhancing safety and scalability while maintaining therapeutic efficacy. On May 26, 2025, Neural entered into a Strategic Investment and Option Agreement with CWE European Holdings Inc., a leading CBD hemp retailer in Germany operating under the brand to acquire up to 100% of CWE through a multi-stage transaction. The transaction is expected to expand Neural's commercial footprint in Europe while maintaining its core commitment to drug discovery and mental health innovation. For further inquiries, please contact:Neural Therapeutics Inc. Ian Campbell, CEOE: icampbell@ T: +1 (647) 697-NURL (6875) Marc LakmaakerE: mlakmaaker@ +1.647.289.6640 CAUTIONARY DISCLAIMER STATEMENT No securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of the contents of this news release. This news release contains forward-looking statements ("FLS") relating opening of new franchise locations by CWE (operating as the timing and scope of participation at Mary Jane Berlin 2025, the growth and performance of business, Neural's indirect exposure to such growth through its investment in CWE, and Neural's continued focus on ethnobotanical drug discovery. FLS may also include statements regarding potential synergies from the transaction between Neural and CWE, expected consumer reception of products and projections about European market demand for hemp and CBD-related goods. FLS are often identified by terms such as "will", "may", "should", "anticipate", "expect", "plan" and similar expressions. These statements are not statements of historical fact, but rather predictions about future events, which are inherently subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned should not to place undue reliance on any forward-looking information. Although management considers such information to be reasonable at the time of preparation, may prove to be incorrect and actual outcomes may differ significantly. FLS contained in this news release are expressly qualified by this cautionary statement. The Company expressly disclaims any intention or obligation to update or revise such statements. A description of additional risk factors that may cause actual results to differ materially from FLS in Neural's disclosure documents posted on The securities of Neural have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws. The securities may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons" (as defined in Regulation S under the U.S. Securities Act), unless registered or exempt from registration under the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy Neural's securities in the United States or any other jurisdiction where such an offer or sale would be unlawful. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Neural's Partner CWE to Open Store No. 16 in the City of Bonn and Invitation to Meet Hanf.com at Mary Jane Berlin 2025
Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as one of the Germany's leading CBD retailers, are pleased to provide an update on expansion efforts in Germany. A subsidiary of CWE has signed a franchise agreement to open the first in the City of Bonn-the former capital of The Federal Republic of Germany and home to over 320,000 residents. This marks fifth franchise agreement and the second store in the state of North Rhine-Westphalia. is also proud to announce its participation in Mary Jane Berlin 2025, Europe's premier cannabis trade show and festival, taking place June 19-22, 2025 at Messe Berlin. As part of the event's vibrant exhibition floor, will showcase its latest product innovations, including premium CBD oils, sustainable hemp-based wellness items, and exclusive new lifestyle offerings. Visitors can find at Booth #G19/G20, where they will be invited to explore, sample, and connect with the team behind one of the most trusted names in the hemp space. Alex Cerveny, COO of commented: "We are excited to bring the experience to Bonn-a city with deep roots and a progressive spirit. This new franchise marks an important step in our mission to make high-quality CBD products accessible to customers across Germany. We look forward to serving the Bonn community with the same passion, integrity, and innovation that defines the brand." "We are also thrilled to be part of Mary Jane Berlin again this year and invite our friends, partners, and associates to come meet our team." Mr. Cerveny added: "This event is not just a trade show-it's a celebration of cannabis culture, innovation, and progress. We look forward to engaging with industry partners and consumers to showcase our carefully curated portfolio of CBD products, as we continue paving the way for opening more franchise locations." Now in its ninth year, Mary Jane Berlin is expected to welcome over 60,000 visitors and more than 500 exhibitors from around the world. Programming includes expert panels, live music, food trucks, and a dedicated B2B business day. About Neural Therapeutics Neural Therapeutics is a leader in ethnobotanical drug discovery, focusing on the development of therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. The Company's innovative approach to drug development involves the strategic use of sub-hallucinogenic doses of mescaline extract, enhancing safety and scalability while maintaining therapeutic efficacy. On May 26, 2025, Neural entered into a Strategic Investment and Option Agreement with CWE European Holdings Inc., a leading CBD hemp retailer in Germany operating under the brand to acquire up to 100% of CWE through a multi-stage transaction. The transaction is expected to expand Neural's commercial footprint in Europe while maintaining its core commitment to drug discovery and mental health innovation. For further inquiries, please contact:Neural Therapeutics Inc. Ian Campbell, CEOE: icampbell@ T: +1 (647) 697-NURL (6875) Marc LakmaakerE: mlakmaaker@ +1.647.289.6640 CAUTIONARY DISCLAIMER STATEMENT No securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of the contents of this news release. This news release contains forward-looking statements ("FLS") relating opening of new franchise locations by CWE (operating as the timing and scope of participation at Mary Jane Berlin 2025, the growth and performance of business, Neural's indirect exposure to such growth through its investment in CWE, and Neural's continued focus on ethnobotanical drug discovery. FLS may also include statements regarding potential synergies from the transaction between Neural and CWE, expected consumer reception of products and projections about European market demand for hemp and CBD-related goods. FLS are often identified by terms such as "will", "may", "should", "anticipate", "expect", "plan" and similar expressions. These statements are not statements of historical fact, but rather predictions about future events, which are inherently subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned should not to place undue reliance on any forward-looking information. Although management considers such information to be reasonable at the time of preparation, may prove to be incorrect and actual outcomes may differ significantly. FLS contained in this news release are expressly qualified by this cautionary statement. The Company expressly disclaims any intention or obligation to update or revise such statements. A description of additional risk factors that may cause actual results to differ materially from FLS in Neural's disclosure documents posted on The securities of Neural have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws. The securities may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons" (as defined in Regulation S under the U.S. Securities Act), unless registered or exempt from registration under the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy Neural's securities in the United States or any other jurisdiction where such an offer or sale would be unlawful. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
28-05-2025
- Business
- Yahoo
Neural Therapeutics and Hanf.com Sign Strategic Investment and Option Agreement to Create a Science-Backed Botanical Wellness Leader
Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as a leading German CBD retailer, are pleased to announce the signing of a strategic investment and option agreement dated May 28, 2025 (the "SIO Agreement") for Neural to acquire an interest in CWE through a series of transactions (the "CWE Transactions"). Ian Campbell, CEO of Neural commented: "We are very pleased to finalize an agreement with This is an important milestone in our strategy to build our asset base by making an investment into a revenue-generating and profitable health and wellness business. As we continue to advance our pharmaceutical and nutraceutical research and development programs, we expect that our partnership with will be a key aspect of long-term value creation." Ronnie Jaegermann, CEO of CWE, commented: "We are glad to have reached this milestone with Neural. The proposed investment is expected to provide CWE with much needed visibility in the public markets, especially during a time of rapid growth in the European CBD and cannabis markets. As we continue to execute our growth-through-franchising strategy we look forward to working with Neural as we achieve new heights." Strategic Rationale and Overview of The proposed investment is expected to bring together Neural's R&D and intellectual property in psychedelics and botanicals with high-traffic retail and digital distribution network across Germany- one of the largest cannabinoid markets in Europe. The transactions contemplated by the SIO Agreement, if completed, will mark a transformative milestone for Neural as it diversifies its business through a strategic investment into a revenue-generating business with a pulse in a key European wellness market, while maintaining its core focus on psychedelic drug discovery and nutraceutical product development. The investment is also expected to provide Neural with valuable real-time consumer behavior data, enabling the company to iterate and refine its nutraceutical offerings more effectively. enters this agreement with Neural with a solid financial base and demonstrated operational scale. operates 14 retail stores across Germany, supported by a growing e-commerce platform generating approximately €40,000 in monthly direct-to-consumer sales. In addition, its wholesale operations, which serve over 40 independent retailers and kiosks, contribute roughly €100,000 in monthly B2B revenue. Across all channels, has estimated fiscal 2024 revenues total approximately CAD $7.1 million with an estimated net income margin of approximately 13% (unaudited figures, based on preliminary estimates). Management expects revenue growth to continue in 2025, driven by continued retail expansion and increasing franchise contributions. established footprint of retail stores owned and franchised across Germany and a high-performing e-commerce platform would give Neural potential access to a ready-made distribution engine for consumer wellness products. For Neural brings validated formulations, proprietary extraction techniques, and an experienced team of scientists and medical advisors - resources that will enhance ability to launch differentiated wellness products in a competitive and fast-evolving market. Neural's leadership in botanical therapeutics aligns with vision of becoming more than just a retailer, evolving into a vertically integrated wellness brand. Through this proposed alliance, could introduce its customer base to novel, clinically grounded supplements and natural therapies, thereby expanding basket size and brand loyalty. Management believes that together, Neural and could form a cross-continental, science-driven wellness platform with the capability to lead the next wave of cannabinoid and psychedelic innovation in both consumer and regulated therapeutic markets. Cannabis-Club München To view an enhanced version of this graphic, please visit: Cannabis-Club Augsburg To view an enhanced version of this graphic, please visit: Cannabis-Club Ingolstadt To view an enhanced version of this graphic, please visit: Overview of CWE Transaction Further to the Neural press release dated October 3, 2024, the letter of intent between CWE and Neural (the "LOI") stipulated a series of transactions whereby Neural would have an option to acquire an equity interest in CWE. The SIO Agreement replaces the LOI in its entirety and sets definitive terms for the CWE Transactions. The commercial terms remain substantially similar to those stipulated in the LOI, with further details set out below. Under the terms of the SIO Agreement, Neural has been granted a two-part investment option to acquire up to 100% of the issued and outstanding shares of CWE through a series of statutory amalgamations under the Business Corporations Act (Ontario). Assuming that the conditions to closing are satisfied, the CWE Transactions will proceed in two stages: (i) an initial acquisition of a minority 30.61% equity interest in CWE (the "Series A Option"), and (ii) a subsequent acquisition of the remaining 69.39% equity interest in CWE (the "Series B Option"). No finders' fees are payable in connection with the transactions stipulated pursuant to the SIO Agreement. A copy of the SIO Agreement has been filed on Neural's issuer profile on SEDAR+ at and a summary of the material terms is provided below. Series A Option The Series A Option, involves the combination of CWE Newco A (an entity to be formed that will hold 30.61% of the outstanding shares of CWE ("CWE Shares") and which will be owned by certain former CWE shareholders) and Neural Subco A (an entity to be formed and 100% owned by Neural) through a statutory three-cornered amalgamation ("Amalgamation A"), resulting in a new wholly-owned subsidiary ("Amalco A") of Neural. In connection with Amalgamation A, Neural will issue 80,000,000 common shares in the capital of Neural ("Neural Shares") at a deemed price of $0.05 per Neural Share to the holders of Neural Subco A, based on an exchange ratio of 4 Neural Shares for each 1 CWE Share held by CWE Newco A. Following the completion of Amalgamation A, Neural will hold an indirect 30.61% equity interest in CWE through Amalco A. Completion of Amalgamation A is subject to the satisfaction of a number of conditions, including but not limited to the following: CWE completing a series of share exchange transactions ("CWE Reorganization"), which are subject to approval by CWE shareholders ("CWE Shareholders"), whereby such CWE Shareholders will exchange their CWE Shares for shares three newly formed entities ("CWE Newcos" and each a "CWE Newco") for the purpose of completing the CWE Transactions set out in the SIO Agreement; Completion of due diligence by each of Neural and CWE to their respective satisfaction, including receipt of satisfactory financial statements and corporate records; Approval of the Canadian Securities Exchange ("CSE") to complete the transactions stipulated by the exercise of Series A Option; and Other customary conditions such as receipt of certificates, absence of material adverse changes, securing requisite approvals under applicable corporate and securities laws, and the representations and warranties made by each of the parties in the SIO Agreement being true in all material respects at closing of Amalgamation A. Issuance of the Neural Shares pursuant to the exercise of the Series A Option will not constitute a Fundamental Change[1] (as such term is defined in the CSE policies) due to: a) the number of Neural Shares to be issued as consideration for Amalgamation A not exceeding the number of Neural Shares issued and outstanding immediately prior to Amalgamation A; b) new holders of Neural Shares not holding greater than 50% of the voting securities of Neural; c) no changes in the board or management of Neural are expected to occur in connection with Amalgamation A; d) no new Control Person1 will be created as a result of Amalgamation A; and e) no change in voting control of Neural will occur as a result of Amalgamation A. CWE and Neural are arm's length parties and none of the Neural Shares to be issued in connection with Amalgamation A will be issued to Neural's Related Persons1 and Amalgamation A is not considered to be a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). Following the completion of Amalgamation A, Neural does not anticipate any material changes to its current business operations or strategic direction. Neural will continue to advance its ethnobotanical drug discovery programs, including recently announced progress on its intellectual property portfolio (see Neural press release dated April 14, 2025) and permitting progress in Peru (see Neural press release dated May 9, 2025). As completion of Amalgamation A remains subject to the satisfaction or waiver of various conditions, there can be no assurance that Amalgamation A will be completed on the terms contemplated or at all. If completed, Amalgamation A may subject Neural to additional continuous disclosure obligations and regulatory requirements, including ongoing financial reporting obligations in respect of the business acquired. If Neural is not able to meet such requirements it may result in adverse effects on the Company. Series B Option Following the completion of Amalgamation A, Neural will have the right, but not the obligation, to exercise the Series B Option, which involves delivering to CWE a notice of Neural's intention to proceed with Amalgamations B and C ("Series B Transactions"). The Series B Transactions will be effected through a sequence of statutory three-cornered amalgamations involving CWE Newco B and CWE Newco C (which will, following the completion of the CWE Reorganization, hold 31.02% and 38.36% of the issued and outstanding CWE Shares, respectively) and Neural's wholly owned subsidiaries, Neural Subco B and Neural Subco C. As consideration for the Series B Transactions, Neural will issue an aggregate of 173,271,572 Neural Shares, of which: CWE Newco B shareholders will receive four Neural Shares for each CWE Newco B share held, or an aggregate of 81,087,629 Neural Shares at a deemed issue price per Neural Share equal to the greater of: a) $0.05; and b) the price that equal to the Maximum Permitted Discount[2] ("Share Issuance Price"); and CWE Newco C shareholders will receive 3.677309 Neural Shares for every CWE Newco C shares held, or an aggregate of 92,183,943 Neural Shares at a deemed issue price equal to the Share Issuance Price. In addition, holders of previously issued common share purchase warrants of CWE ("CWE Prior Warrants") will receive four common share purchase warrants of Neural ("Neural Compensation Warrants") in exchange for each CWE Prior Warrant, or an aggregate of 130,136,888 Neural Compensation Warrants, exercisable into Neural Shares at a price of $0.14 per Neural Share until April 7, 2027. The Series B Option may only be exercised after the completion of Amalgamation A and is subject to the satisfaction or waiver of a number of conditions, including but not limited to the following: Approval by the board of directors of Neural to proceed with the Series B Transactions; Completion of the CWE Reorganization; Receipt of all required consents and approvals, including approval of Neural Shareholders if required under applicable corporate law and the policies of the CSE; Completion of satisfactory due diligence and financial statement delivery by CWE, as outlined in the SIO Agreement; Neural arranging for a transfer of an aggregate of 8,089,321 Neural Shares to the shareholders of CWE Newco C in accordance with the terms of the SIO Agreement, aimed at equalizing the total aggregate consideration received by the shareholders of CWE Newco C with those of former shareholders of CWE Newco A and CWE Newco B. CSE confirmation that the Series B Transactions may proceed, including any applicable escrow or resale restrictions; and Other customary conditions such as the absence of material adverse changes and the continued truth of representations and warranties made by each of the parties at closing of the Series B Transactions. Upon and as a condition of completion of the Series B Transactions, Neural intends to (i) change its corporate name to " Inc." or such other name as may be approved by the board and the applicable regulatory authorities; (ii) consolidate its share capital on a 4-for-1 basis (the "Neural Consolidation"); and (iii) reconstitute its board of directors to include appointees from both parties as previously agreed upon by each of Neural and CWE in the LOI (the "Neural Director Appointments"). Upon completion of the Series B Transactions, it is anticipated that Neural will, subject to CSE approval and confirmation from former CWE shareholders representing the CWE Newcos, reconstitute its board of directors and senior officers as follows, with four directors to be appointed by CWE and one by Neural, and subject to at least three directors meeting the independence criteria under NI 52-110 - Audit Committees. Completion of the Series B Option, if exercised, will constitute a Fundamental Change[3] under the policies of the CSE, and is subject to additional regulatory requirements, including preparation and filing of a comprehensive listing statement. If completed, Neural does not expect that the transactions underlying the exercise of Series B Option, will involve any parties considered "related parties" of Neural under MI 61-101 immediately prior to such transactions. Neural will evaluate the requirements under MI 61-101 at the time the Series B Option is considered for exercise and complete any applicable disclosure and approval processes required under applicable securities laws. There can be no assurance that Neural will proceed with or complete the Series B Transactions, or that all conditions to complete the Series B Transactions will be satisfied or waived in a timely manner or at all. If completed, the Series B Transactions may subject Neural to additional continuous disclosure obligations and regulatory requirements, including ongoing financial reporting obligations in respect of the business acquired. If Neural is not able to meet such requirements it may result in adverse effects on the Company. Other Material Provisions of the SIO Agreement The SIO Agreement contains several additional material provisions, including: CWE has confirmed that it and its subsidiaries are, and will be at the closing date of each of Amalgamation A and the Series B Transactions, in material compliance with applicable German laws and regulations relevant to their operations, including those governing the manufacture, sale, and distribution of controlled substances; the licensing and regulation of medical products; and the oversight of food safety and consumer protection standards in Germany. As of the date of the SIO Agreement, CWE has 65,340,211 CWE Shares issued and outstanding. CWE has provided a financial statement undertaking pursuant to the SIO Agreement committing to deliver audited consolidated financial statements for the fiscal years ending December 31 2024 and 2023, unaudited interim statements for the three months ending March 31, 2025, auditor reviewed statements for the period ending July 31, 2025, and subsequent quarterly financial updates post-Amalgamation A. CWE has also agreed to provide supporting documentation to facilitate Neural's fair value allocation and internal reporting requirements. Neural Shares issued pursuant to Amalgamation A and the Series B Transactions will be issued under exemptions available under NI 45-106 - Prospectus Exemptions and will not be subject to resale restrictions under NI 45-102 - Resale of Securities or CSE policies and will not bear restrictive legends, except for any securities subject to applicable escrow provisions of NP 46-201 - Escrow for Initial Public Offerings. Neural Shares issued pursuant to the Series B Transactions will be issued under exemptions available under NI 45-106 - Prospectus Exemptions, will not be subject to resale restrictions under NI 45-102 - Resale of Securities or CSE policies and will not bear restrictive legends, except for any securities subject to applicable escrow provisions of NP 46-201 - Escrow for Initial Public Offerings. CWE has agreed to prepare and deliver all required documentation to its shareholders in accordance with applicable laws to approve the transactions contemplated in the SIO Agreement, including the CWE Reorganization and the execution of share exchange agreements and related documents necessary to complete each of Amalgamation A and the Series B Transactions, by legally permissible means. The SIO Agreement includes a put option mechanism in favour of Neural (the "Put Option") to protect its interests in the event that required financial disclosure obligations or other conditions are not met following the completion of Amalgamation A. If CWE fails to deliver the requisite financial statements or satisfy certain post-closing obligations, Neural may elect to unwind Amalgamation A by exercising the Put Option within a specified timeframe. Upon exercise, CWE will issue to Neural a secured convertible promissory note in the principal amount equal to the value of the Neural Shares issued in Amalgamation A, secured by a general security agreement over the assets of CWE and be convertible into CWE Shares at a pre-agreed valuation. The Put Option is designed to provide Neural with a contractual remedy in lieu of a formal rescission process, while preserving its ability to re-engage in a potential acquisition of CWE if the deficiencies are subsequently cured. About Neural Therapeutics Neural Therapeutics is a leader in ethnobotanical drug discovery, focusing on the development of therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. The Company's innovative approach to drug development involves the strategic use of sub-hallucinogenic doses of mescaline extract, enhancing safety and scalability while maintaining therapeutic efficacy. On May 26, 2025, Neural entered into a Strategic Investment and Option Agreement with CWE European Holdings Inc., a leading CBD hemp retailer in Germany operating under the brand to acquire up to 100% of CWE through a multi-stage transaction. The transaction to acquire CWE, if completed, is expected to expand Neural's commercial footprint in Europe while maintaining its core commitment to drug discovery and mental health innovation. For further inquiries, please contact: Neural Therapeutics Inc. Ian Campbell, CEOE: icampbell@ T: +1 (647) 697-NURL (6875) Marc LakmaakerE: mlakmaaker@ +1.647.289.6640 CAUTIONARY DISCLAIMER STATEMENT No securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements ("FLS") relating to the outlook for psychedelic markets and related industries, the achievement, and the timing of, certain development milestones and the successful execution of Neural's business strategy, , Neural's expectations regarding diversification into consumer wellness markets while maintaining its focus on psychedelic and ethnobotanical drug discovery; projected financial performance and growth of the completion, structure, and timing and ability of completing the transactions contemplated under the SIO Agreement (including Amalgamation A and the Series B Transactions and receipt of all regulatory and shareholder approvals in connection therewith); the anticipated composition of Neural's future board and management team; the anticipated value creation associated with the proposed transactions; the plans for the combined entity and the ability to maintain Neural's CSE listing and the reporting issuer status in good standing. FLS are often identified by terms such as "will", "may", "should", "anticipate", "expect", "plan" and similar expressions. These statements are not statements of historical fact, but rather predictions about future events, which are inherently subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Key factors that could cause actual results to differ materially from the Company's expectations include the ability to satisfy the conditions to complete Amalgamation A and the Series B Transactions; if such transactions are completed, the ability to execute on the proposed business plans for the entity; the inability to raise sufficient funds to execute Neural's business plan; failure to satisfy the conditions imposed by relevant regulators, regulatory restrictions and approvals related to psychedelic-based drug research and development, unforeseen delays in securing intellectual property protections, changes in government regulations and policies impacting Neural's operations; and general economic, market, or industry conditions. Readers are cautioned that assumptions used in preparing any forward-looking information may prove to be incorrect. Future events or circumstances could cause actual results to differ materially from those projected due to numerous known and unknown risks, uncertainties, and other factors, many of which are beyond Neural's control. Reader should not place undue reliance on any forward-looking information. Although management considers such information to be reasonable at the time of preparation, may prove to be incorrect and actual outcomes may differ significantly. FLS contained in this news release are expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the expectations of the Company as of the date hereof and is subject to change. The Company expressly disclaims any intention or obligation to update or revise such statements. A description of additional risk factors that may cause actual results to differ materially from FLS in Neural's disclosure documents posted on The securities of Neural have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws. The securities may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons" (as defined in Regulation S under the U.S. Securities Act), unless registered or exempt from registration under the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy Neural's securities in the United States or any other jurisdiction where such an offer or sale would be unlawful. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. [1] As such terms are defined in the CSE Policies.[2] As such term is defined in the CSE Policies.[3] As such terms are defined in the CSE Policies. To view the source version of this press release, please visit
The Hindu
21-04-2025
- Politics
- The Hindu
Gunmen attack Chinese-owned power plant site in Chile
Gunmen attacked a Chinese-owned hydroelectric plant under construction in Chile Sunday, setting fire to dozens of trucks and heavy earth-moving equipment, police said. The Rucalhue power plant is being built by Rucalhue Energia Spa, a unit of China International Water and Electric Corporation (CWE), and is projected to cost $350 million. It is being built along the Biobio, one of Chile's main rivers, and is opposed by Indigenous people who say it will harm the environment. Security guards at the job site said assailants with guns showed up and threatened them. They then "proceeded to burn all the equipment there was at the site," said police chief Renzo Miccono. The attackers burned 45 trucks and five pieces of earth-moving equipment, he said. Two security guards were wounded in the attack on the site, which is 550 kilometres (340 miles) south of Santiago. China's foreign ministry on Monday condemned the attack and said it had been in touch with Chilean officials on "concrete measures to protect the safety of Chinese companies' projects and personnel." "The Chinese side... is willing to closely work with the Chilean side to carry out relevant investigations and follow-up actions," spokesman Guo Jiakun told a news briefing. Chilean Security Minister Luis Cordero told local media that given where and how the attack was carried out it was "of a terrorist nature." Rucalhue Energia Spa said the cost of the damage was being evaluated.
Forbes
17-04-2025
- Forbes
CVE's Near Cybersecurity Miss Averted — But The World Must Step Up
The cybersecurity world, shocked by the near-shutdown of the CVE system — a quiet crisis that nearly ... More disrupted the backbone of global vulnerability coordination. In cybersecurity, some moments pass quietly. Others expose deep fault lines. The near shutdown of the Common Vulnerabilities and Exposures Program — operated by MITRE and funded by the United States Cybersecurity and Infrastructure Security Agency — was the latter. With just hours left before funding expired, CISA, already operating under intense budget pressure, extended the contract and narrowly averted disruption to the backbone of global vulnerability coordination. This wasn't a budget hiccup or a DOGE sensational headline. It was a warning flare. For more than two decades, CVE has served as the global catalog of known cybersecurity vulnerabilities. Everyone — from intelligence agencies and infrastructure operators to security vendors and open-source developers — relies on it. Yet one nation has carried the cost while the entire world benefits. That model is no longer sustainable — and it never truly was. MITRE is a federally funded research and development center — a nonprofit that operates exclusively in the public interest. It runs multiple research centers on behalf of agencies like the Department of Defense, Department of Homeland Security, Federal Aviation Administration and the Centers for Medicare and Medicaid Services. Unlike commercial firms, MITRE doesn't sell products or compete for private contracts. Its mandate is to solve problems too complex, sensitive or mission-critical for the private sector to address alone. In cybersecurity, MITRE is best known for stewarding: • CVE: Common Vulnerabilities and Exposures, the global identifier system for software flaws • ATT&CK: a framework of adversary tactics and techniques • CWE: Common Weakness Enumeration, a catalog of software design weaknesses MITRE operates quietly but critically — a trusted technical authority at the center of digital defense. And for the record — MITRE doesn't stand for anything. It's a legacy name, like RAND. Originally affiliated with the Massachusetts Institute of Technology, the organization has long since outgrown its acronymic roots. CVE is the Rosetta Stone of vulnerability management. Every known software flaw receives a unique identifier, enabling defenders, vendors and governments to coordinate response, issue guidance and deploy patches with precision. Without CVE: • Teams use inconsistent naming conventions • Alerts become fragmented • Security tools lose interoperability • Threat intelligence sharing breaks down As Jen Easterly, the prior Director of CISA, noted this week, CVE is more than a database — it is 'a pillar of operational resilience and national security.' And it came dangerously close to collapse. The Trump administration has made clear its intent to streamline federal spending and question programs that do not yield direct national benefit. Whether this latest contract drama was the result of oversight or intentional brinkmanship, the outcome is the same — a critical global system was nearly put at risk because of domestic budget negotiations. So the shock to the system happened. On April 15, MITRE issued a stunning warning: funding for the CVE system would expire within 24 hours. The cybersecurity community responded with alarm. A breakdown in this system would mean chaos — confusion among defenders, delayed patching and increased exposure to active threats. Hours before the deadline, CISA issued an eleven-month extension. But while the short-term crisis was averted, the structural risk remains. CVE is a global system — yet it lives entirely on American funding. Since 1999, MITRE has operated CVE under U.S. government sole sponsorship. That funding has enabled a global system — but the burden has fallen squarely on one agency, and one country. The European Union has its own database, but it is largely unknown. Nations across Asia, the Middle East Gulf States and beyond all consume CVE data and build tools around it — without meaningful financial contribution. Meanwhile, cybersecurity vendors spend millions annually on conference booths, marketing activations and branded swag. Redirecting even a fraction of those budgets toward shared infrastructure like CVE would likely do more to secure their customers — and strengthen their credibility — than another oversized LED wall or fancy drone display at the upcoming RSA conference. This crisis genuinly creates the opportunity for reform. A newly announced nonprofit — the CVE Foundation — has emerged as a potential future steward of the CVE system. This is the right move — but it needs broad support, generous funding and real structure. The best solution is to transition CVE to a multi-stakeholder foundation model, governed by both private industry and international governments, with MITRE as the technical anchor — not the financial underwriter. Here's what that model should include: • Private Sector Co-Funding: Security vendors, cloud providers and software giants should contribute proportionally. They all benefit from CVE — it's time they help sustain it. In fact, this may be one of the highest-return investments a company can make from its marketing budget. • Global Buy-In and Funding: Countries outside the United States must step up. The European Union maintains its own vulnerability catalog, but it lacks global adoption and visibility. CVE has become the de facto international standard — the common language for cybersecurity coordination across borders. It's time for allied nations, especially those who rely on CVE for their own national defense and critical infrastructure, to redirect a portion of their cybersecurity budgets toward sustaining this shared system. Funding a globally relied-upon platform is not charity — it's strategic investment in collective resilience. • Independent Oversight: The new CVE Foundation must be neutral, community-driven and resilient — free from sole reliance on any one government. Let MITRE continue operating CVE. Their technical stewardship is excellent. But move the financial dependency to a diversified global model before the next contract cliff. The near-collapse of CVE was a stark reminder of just how fragile our cybersecurity foundations can be. It exposed the risks of relying on a single point of failure — and the assumption that one nation will indefinitely shoulder the weight of a global system. This isn't about blame. It's about modernization. A vulnerability catalog used by every business and government on Earth cannot hinge on the budget cycles of a single capital. The system held — for now. But what comes next must be deliberate, strategic and shared. Why should American taxpayers alone fund a tool the entire world depends on? Should the security of our digital infrastructure rise and fall with domestic politics? If the world relies on CVE — the world must help fund CVE.
